Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864316 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL5575741 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL7497018 | 0.98 | ALDH1A1 (0.53) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL7495284 | 0.93 | ALDH1A1 (0.48) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL8393221 | 0.88 | — | — | |
| SCHEMBL6677988 | 0.88 | — | — | |
| SCHEMBL6064540 | 0.80 | TP53 (0.50) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL6442424 | 0.80 | TP53 (0.50) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1698454 | 0.80 | TP53 (0.56) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E | |
| SCHEMBL28480892 | 0.79 | ALDH1A1 (0.77) | ALDH1A1TP53SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4015529-A1 | G PROTEIN PEPTIDOMIMETICS | Vrije Universiteit Brussel (BE) | 2022-06-22 | — | — | EP | disclosed |
| US-7589196-B2 | Amine-substituted biphenyldiphosphines | SOLVIAS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| EP-2039361-A2 | Use of immunomodulatory compounds | Eisai R&D Management Co., Ltd. (JP) | 2009-03-25 | — | — | EP | disclosed |
| CN-1900080-A | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2007-01-24 | — | — | CN | disclosed |
| US-20060276643-A1 | Amine-substituted diphenyldiphosphines | FAURECIA SYSTEMES D'ECHAPPEMENT (FR) | 2006-12-07 | — | — | US | disclosed |
| CN-1269822-C | Inhibitors of kruenza protease and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2006-08-16 | — | — | CN | disclosed |
| CN-1486320-A | Inhibitors of kruenza protease and other cysteine proteases | ��ķ��ҽ������˾ | 2004-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276643-A1 | Amine-substituted diphenyldiphosphines | DDC, PNMT, DDT | ALDH1A1 389/4885TP53 3945/4885SMN1; SMN2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.